133 related articles for article (PubMed ID: 22918719)
1. Metabolism of patupilone in patients with advanced solid tumor malignancies.
Kelly KR; Zollinger M; Lozac'h F; Tan E; Mita A; Waldmeier F; Urban P; Anand S; Wang Y; Swart P; Takimoto C; Mita M
Invest New Drugs; 2013 Jun; 31(3):605-15. PubMed ID: 22918719
[TBL] [Abstract][Full Text] [Related]
2. Mass balance study of [¹⁴C]eribulin in patients with advanced solid tumors.
Dubbelman AC; Rosing H; Jansen RS; Mergui-Roelvink M; Huitema AD; Koetz B; Lymboura M; Reyderman L; Lopez-Anaya A; Schellens JH; Beijnen JH
Drug Metab Dispos; 2012 Feb; 40(2):313-21. PubMed ID: 22041109
[TBL] [Abstract][Full Text] [Related]
3. Phase I dose-finding study of weekly single-agent patupilone in patients with advanced solid tumors.
Rubin EH; Rothermel J; Tesfaye F; Chen T; Hubert M; Ho YY; Hsu CH; Oza AM
J Clin Oncol; 2005 Dec; 23(36):9120-9. PubMed ID: 16301595
[TBL] [Abstract][Full Text] [Related]
4. Effects of patupilone on the pharmacokinetics and pharmacodynamics of warfarin in patients with advanced malignancies: a phase I clinical trial.
Tsimberidou AM; Takimoto CH; Moulder S; Uehara C; Mita M; Mita A; Urban P; Tan E; Wang Y; Vining D; Kurzrock R
Mol Cancer Ther; 2011 Jan; 10(1):209-17. PubMed ID: 21220503
[TBL] [Abstract][Full Text] [Related]
5. Metabolism, excretion, and pharmacokinetics of oral brivanib in patients with advanced or metastatic solid tumors.
Mekhail T; Masson E; Fischer BS; Gong J; Iyer R; Gan J; Pursley J; Patricia D; Williams D; Ganapathi R
Drug Metab Dispos; 2010 Nov; 38(11):1962-6. PubMed ID: 20671097
[TBL] [Abstract][Full Text] [Related]
6. Patupilone (epothilone B) for recurrent glioblastoma: clinical outcome and translational analysis of a single-institution phase I/II trial.
Oehler C; Frei K; Rushing EJ; McSheehy PM; Weber D; Allegrini PR; Weniger D; Lütolf UM; Knuth A; Yonekawa Y; Barath K; Broggini-Tenzer A; Pruschy M; Hofer S
Oncology; 2012; 83(1):1-9. PubMed ID: 22688083
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of patupilone in patients with advanced ovarian, primary fallopian, or primary peritoneal cancer: a phase I, open-label, dose-escalation study.
Ten Bokkel Huinink WW; Sufliarsky J; Smit WM; Spanik S; Wagnerova M; Hirte HW; Kaye S; Johri AR; Oza AM
J Clin Oncol; 2009 Jul; 27(19):3097-103. PubMed ID: 19451434
[TBL] [Abstract][Full Text] [Related]
8. A phase Ib and pharmacokinetic trial of patupilone combined with carboplatin in patients with advanced cancer.
Forster M; Kaye S; Oza A; Sklenar I; Johri A; Cheung W; Zaknoen S; Gore M
Clin Cancer Res; 2007 Jul; 13(14):4178-84. PubMed ID: 17634546
[TBL] [Abstract][Full Text] [Related]
9. Human mass balance study of the novel anticancer agent ixabepilone using accelerator mass spectrometry.
Beumer JH; Garner RC; Cohen MB; Galbraith S; Duncan GF; Griffin T; Beijnen JH; Schellens JH
Invest New Drugs; 2007 Aug; 25(4):327-34. PubMed ID: 17347871
[TBL] [Abstract][Full Text] [Related]
10. Mass balance, routes of excretion, and pharmacokinetics of investigational oral [
Zhou X; Pusalkar S; Chowdhury SK; Searle S; Li Y; Ullmann CD; Venkatakrishnan K
Invest New Drugs; 2019 Aug; 37(4):666-673. PubMed ID: 30397836
[TBL] [Abstract][Full Text] [Related]
11. A Phase I Clinical, Pharmacokinetic, and Pharmacodynamic Study of Weekly or Every Three Week Ixabepilone and Daily Sunitinib in Patients with Advanced Solid Tumors.
Montero AJ; Kwon D; Flores A; Kovacs K; Trent JC; Benedetto P; Rocha-Lima C; Merchan JR
Clin Cancer Res; 2016 Jul; 22(13):3209-17. PubMed ID: 26864210
[TBL] [Abstract][Full Text] [Related]
12. Use of epothilone B (patupilone) in refractory lymphoma and advanced solid tumors in dogs.
Meier V; Geigy C; Grosse N; McSheehy P; Rohrer Bley C
J Vet Intern Med; 2013; 27(1):120-5. PubMed ID: 23205945
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo.
O'Reilly T; Wartmann M; Brueggen J; Allegrini PR; Floersheimer A; Maira M; McSheehy PM
Cancer Chemother Pharmacol; 2008 Nov; 62(6):1045-54. PubMed ID: 18301895
[TBL] [Abstract][Full Text] [Related]
14. Continuous low-dose infusion of patupilone increases the therapeutic index in mouse and rat tumour models.
Becquet M; Laborde L; Texier C; Sterker D; Gschwind HP; Pfaar U; Wartmann M; O'Reilly TM; McSheehy PM
Anticancer Drugs; 2018 Aug; 29(7):691-701. PubMed ID: 29734209
[TBL] [Abstract][Full Text] [Related]
15. Clinical activity of patupilone in patients with pretreated advanced/metastatic colon cancer: results of a phase I dose escalation trial.
Melichar B; Casado E; Bridgewater J; Bennouna J; Campone M; Vitek P; Delord JP; Cerman J; Salazar R; Dvorak J; Sguotti C; Urban P; Viraswami-Appanna K; Tan E; Tabernero J
Br J Cancer; 2011 Nov; 105(11):1646-53. PubMed ID: 22027708
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and antitumor activity of patupilone combined with midazolam or omeprazole in patients with advanced cancer.
Tsimberidou AM; Lewis N; Reid T; Burris H; Urban P; Tan EY; Anand S; Uehara C; Kurzrock R
Cancer Chemother Pharmacol; 2011 Dec; 68(6):1507-16. PubMed ID: 21499896
[TBL] [Abstract][Full Text] [Related]
17. Phase I clinical, pharmacokinetic, and pharmacodynamic study of KOS-862 (Epothilone D) in patients with advanced solid tumors and lymphoma.
Konner J; Grisham RN; Park J; O'Connor OA; Cropp G; Johnson R; Hannah AL; Hensley ML; Sabbatini P; Mironov S; Danishefsky S; Hyman D; Spriggs DR; Dupont J; Aghajanian C
Invest New Drugs; 2012 Dec; 30(6):2294-302. PubMed ID: 22072399
[TBL] [Abstract][Full Text] [Related]
18. Patupilone in cancer treatment.
Bystricky B; Chau I
Expert Opin Investig Drugs; 2011 Jan; 20(1):107-17. PubMed ID: 21142807
[TBL] [Abstract][Full Text] [Related]
19. Novel physiologically based pharmacokinetic modeling of patupilone for human pharmacokinetic predictions.
Xia B; Heimbach T; Lin TH; He H; Wang Y; Tan E
Cancer Chemother Pharmacol; 2012 Jun; 69(6):1567-82. PubMed ID: 22526410
[TBL] [Abstract][Full Text] [Related]
20. Phase I trial of ixabepilone administered as three oral doses each separated by 6 hours every 3 weeks in patients with advanced solid tumors.
Kunz PL; He AR; Colevas AD; Pishvaian MJ; Hwang JJ; Clemens PL; Messina M; Kaleta R; Abrahao F; Sikic BI; Marshall JL
Invest New Drugs; 2012 Dec; 30(6):2364-70. PubMed ID: 22331549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]